RxSight stock faces 19% revenue drop as turnaround shifts to 2027
Published on 11/13/2026 at 00:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTurnaround pressure meets restructuring
- Third-quarter revenue fell as competitive pressure weighed on Light Adjustable Lens demand.
- RxSight is expanding its US sales force while restructuring is intended to reduce operating expenses from 2027.
- The Alcon collaboration delivered a USD 60 million payment and remains part of the longer-term growth plan.
RxSight reported weaker third-quarter results on November 3, 2026, as revenue fell 19% year over year to USD 24.6 million. The company cited ongoing competitive pressure, while the net loss widened to USD 16.2 million from USD 9.8 million a year earlier. The figures were published by Nasdaq.
Lens demand remains under pressure
Light Adjustable Lens procedure volume fell 11% year over year to 23,128 units. Gross margin declined to 73.6% from 79.9% in the prior-year quarter, with RxSight pointing to higher inventory reserves and increased inventory costs for its lens and light-delivery products.
The company reported a GAAP loss of USD 0.39 per share, compared with a loss of USD 0.24 per share in the third quarter of 2025. Adjusted net loss was USD 8.6 million, or USD 0.21 per share, versus USD 1.7 million, or USD 0.04 per share, a year earlier.
Sales rebuild targets 2027
RxSight said it is nearly doubling its US sales force and has added Taryn Conway as chief commercial officer and Frank Shields as executive vice president for sales and commercial strategy. A broad restructuring is intended to align resources with strategic priorities and generate meaningful operating expense savings in 2027 and beyond.
The company did not provide formal full-year 2026 guidance. Management plans to resume guidance for 2027 with the fourth-quarter results, leaving investors focused on whether the planned commercial rebuild can stabilize lens utilization.
RxSight's focused eye-care model
RxSight is a commercial-stage ophthalmic medical technology company based in the United States. Its FDA-approved Light Adjustable Lens system combines adjustable intraocular lenses, a Light Delivery Device and related accessories to customize vision after cataract surgery.
The company focuses on post-cataract vision correction rather than operating as a diversified eye-care group. Its current strategy centers on expanding physician engagement, supporting practices and developing its collaboration with Alcon.
RxSight at a glance
- Company: RxSight, Inc.
- ISIN: US78349D1072
- Ticker: RXST
- Home exchange: Nasdaq
- Third-quarter revenue: USD 24.6 million for the quarter ended September 30, 2026
- Cash, cash equivalents and short-term investments: USD 254.7 million as of September 30, 2026
US equities are tracked through the S&P 500.
